Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long Term GLP-1 Receptor Agonist Treatment of self pay patients : A Retrospective Analysis

This retrospective analysis of 572 self-pay patients on a US telehealth platform reveals that while long-term GLP-1 RA treatment yields substantial weight loss comparable to clinical trials, significant gender disparities exist where females achieve higher rates of major weight loss but males demonstrate greater platform engagement, suggesting that current "one-size-fits-all" telehealth models may require tailored strategies to address biological and behavioral differences.

The Gist

🍎 The Big Picture: A "Real-World" Test Drive

Imagine the clinical trials for weight-loss drugs (like Semaglutide and Tirzepatide) are like Formula 1 race cars being tested on a perfect, closed track with a pit crew, unlimited fuel, and the best drivers. They go incredibly fast and win every race.

This study asks: "What happens when regular people buy these cars, drive them on bumpy city streets, pay for their own gas out of their own pockets, and don't have a pit crew?"

The researchers looked at data from 572 people in the US who used a telehealth app to get these drugs. Crucially, these people were "self-pay," meaning they didn't have insurance covering the cost; they paid every single dollar themselves. This is important because paying out-of-pocket changes how people behave (e.g., maybe they skip a dose to save money).

📉 The Results: How Much Weight Did They Lose?

1. The "Magic" Drugs Worked (Mostly)

• The Good News: Almost everyone (96%) lost weight. On average, people lost about 13-14% of their body weight over a year. That's a huge amount!
• The Analogy: Think of the drugs as a powerful turbocharger for your metabolism. For most people, it worked just as well as the "race track" tests predicted.

2. The Surprise: The "Newer" Drug Didn't Win

• The Expectation: The newer drug, Tirzepatide, was supposed to be the "Super Turbo" that beats the older drug, Semaglutide. In the official trials, it did.
• The Reality: In this real-world group, both drugs worked about the same.
• Why? The researchers suspect it's a money issue. Tirzepatide is expensive. In a perfect trial, doctors force patients to take the highest dose. In the real world, if a patient is paying $1,000+ a month, they might stay on a lower, cheaper dose to keep their wallet happy. Lower dose = less weight loss.

👩‍🦰 vs. 👨‍🦱 The Gender Gap: The "Quiet Achiever" vs. The "Anxious Driver"

This is the most interesting part of the study. The researchers found a funny split between men and women.

The Women (The "Quiet Achievers")

• Who they are: They made up 80% of the group.
• How they did: They lost more weight than the men. A huge chunk of them (30%) became "Major Responders" (losing over 20% of their body weight).
• How they used the app: They checked in less often.
• The Analogy: Imagine a woman driving a car that runs perfectly. She doesn't need to call the mechanic every week. She just drives, the car works, and she gets to her destination. She trusts the process.

The Men (The "Anxious Drivers")

• Who they are: They made up 20% of the group.
• How they did: They lost less weight. Only about 6% became "Major Responders." They were twice as likely to be "Non-Responders" (losing almost nothing).
• How they used the app: They checked in much more often. They sent more messages and had more video calls.
• The Analogy: Imagine a man driving a car that feels sluggish. He keeps calling the mechanic, asking, "Is the engine okay? Why isn't it going fast? What should I do?" He is engaging with the system more because he is struggling to get results.
• The Takeaway: Men were trying harder to get help, but their bodies just weren't responding as well as the women's.

🏔️ The "Plateau" Mountain

The study tracked how fast people lost weight over time.

• Months 1–3: Everyone lost weight fast. It was like sliding down a steep, icy hill.
• Months 12–15: The speed slowed down to a crawl.
• The Analogy: Think of it like a roller coaster. You zoom down the first big drop (months 1–3), but eventually, the track flattens out. The drugs don't stop working; your body just adapts and says, "Okay, we've lost enough, let's stop here."
• The Lesson: These drugs aren't a "one-and-done" cure. They are a maintenance tool. Once you hit the flat part of the track, you need a new strategy to keep going.

💡 What Does This All Mean?

1. Telehealth Works: You don't need to go to a fancy clinic to get these drugs to work. A digital app is a great way to manage this, even if you are paying for it yourself.
2. Money Matters: If you are paying out of pocket, you might not get the full "super-dose" effect, which might explain why the newer drug didn't look as amazing as the trials said.
3. One Size Does Not Fit All: The "standard" approach works great for women in this study, but men seem to need a different strategy. Since men were checking in more often but losing less weight, they might need different advice or different dosing to break through their biological resistance.
4. It's a Marathon, Not a Sprint: The weight loss slows down after a year. Patients and doctors need to prepare for this "flat track" and focus on keeping the weight off rather than just trying to lose more.

In short: These drugs are powerful tools that work in the real world, but they aren't magic. They work best when you can afford the full dose, and they might need to be tweaked depending on whether you are a man or a woman.

Technical Summary

1. Problem Statement

While Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and dual GIP/GLP-1 agonists like tirzepatide have demonstrated transformative efficacy in randomized clinical trials (RCTs) for obesity treatment, their translation into routine clinical practice remains poorly characterized. Specifically, there is a lack of Real-World Evidence (RWE) regarding:

• Self-Pay Populations: Patients in Direct-to-Consumer (DTC) telehealth models who bear the full financial cost of therapy, potentially affecting adherence, dose titration, and outcomes compared to insured or trial participants.
• Long-Term Sustainability: The durability of weight loss beyond the initial induction phase in a non-controlled setting.
• Demographic Disparities: The interaction between biological sex, physiological response, and digital engagement patterns (telehealth utilization) in obesity management.

2. Methodology

• Study Design: Retrospective observational analysis of electronic health records (EHR).
• Data Source: CareValidate, a US-based national telehealth platform partner for DTC weight management providers.
• Study Period: January 12, 2024, to December 15, 2025 (703 days).
• Cohort Selection:
  • Initial Pool: 9,442 adults (18+) enrolled in the platform.
  • Inclusion Criteria: Adults with overweight/obesity; prescription of semaglutide or tirzepatide; confirmed "self-pay" status (no insurance claims); minimum follow-up of 9 months.
  • Exclusion: Insured patients, insufficient follow-up (<9 months), or missing data.
  • Final Analytical Cohort: 572 patients (453 females, 119 males).
• Interventions: Continuous treatment with semaglutide (n=450) or tirzepatide (n=122), administered via synchronous (video) or asynchronous (chat) telehealth. Dosing was titrated based on tolerance and financial sustainability.
• Primary Outcome: Percentage Total Body Weight Loss (%TBWL) from baseline to the last recorded encounter.
• Secondary Outcomes:
  • Categorical responder rates (<5%, 5–9.9%, 10–14.9%, 15–19.9%, >20%).
  • Weight loss velocity (lbs/week) across time intervals.
  • Telehealth utilization metrics (total encounters, visit intervals).
• Statistical Analysis: Descriptive statistics, mean/SD comparisons, and significance testing (P < 0.05) using Python.

3. Key Contributions

• Self-Pay Phenotype Characterization: Provides one of the first large-scale analyses of long-term GLP-1 outcomes specifically in a self-pay, uninsured telehealth cohort, isolating the impact of financial barriers on treatment efficacy.
• Gender-Specific Divergence: Uncovers a novel paradox where females constitute the majority of the cohort and achieve superior physiological outcomes, while males demonstrate significantly higher digital engagement (more frequent visits) despite poorer weight loss results.
• Medication Efficacy in Real-World vs. Trials: Contrasts real-world performance of semaglutide and tirzepatide against pivotal RCTs (STEP-1 and SURMOUNT-1), highlighting potential gaps caused by economic constraints on dose titration.
• Kinetic Modeling: Maps the weight loss velocity curve, identifying the peak loss period (Months 1–3) and the subsequent plateau phase (Months 12–15), suggesting a need for care model evolution from "induction" to "maintenance."

4. Results

• Overall Efficacy:
  • 95.8% of patients achieved weight loss; 3.7% experienced weight gain.
  • Semaglutide (n=450): Mean %TBWL at 12 months was 13.8%. This aligns closely with the STEP-1 trial (14.9% at 68 weeks).
  • Tirzepatide (n=122): Mean %TBWL at 12 months was 12.5%. This is significantly lower than the SURMOUNT-1 trial (~20.9% at 72 weeks), though the difference between the two drugs in this study was not statistically significant (P > 0.05).
• Gender Disparities:
  • Physiological Response: Females were significantly more likely to be "Major Responders" (>20% weight loss) compared to males (29.8% vs. 5.9%; P < 0.001). Males had a higher non-responder rate (19.3% vs. 11.9%).
  • Digital Engagement: Contrary to outcomes, males engaged more frequently with the platform. They had a higher mean number of encounters (13.5 vs. 12.7; P = 0.028) and shorter intervals between visits (35.6 days vs. 44.1 days; P = 0.009).
• Weight Loss Velocity:
  • Peak velocity occurred in Months 1–3 (~1.07 lbs/week for both agents).
  • A sharp decline occurred by Months 12–15, indicating a physiological plateau. Semaglutide velocity dropped to 0.16 lbs/week (85% reduction from peak).
• Baseline Predictors: Higher baseline BMI was a significant predictor of response for semaglutide users (Responders: BMI 32.59 vs. Non-responders: BMI 30.12; P = 0.010).

5. Significance and Implications

• Validation of Telehealth Models: The study confirms that telehealth-managed GLP-1 therapy can yield outcomes comparable to clinical trials (specifically for semaglutide) when managed effectively, validating the DTC model for chronic obesity care.
• The "Titration Gap": The underperformance of tirzepatide in this cohort (12.5% vs. ~21% in trials) is likely attributed to economic barriers. Self-pay patients may opt to stay on lower, more affordable doses rather than escalating to maximum tolerated doses, compromising efficacy.
• Personalized Care Strategies: The data suggests a "one-size-fits-all" approach is insufficient.
  • For Males: Higher engagement does not correlate with better outcomes, suggesting a need for distinct titration strategies or behavioral interventions to overcome potential biological resistance or different metabolic responses.
  • For Females: High efficacy with lower engagement suggests current protocols are effective, but retention strategies must shift toward long-term maintenance rather than just weight loss induction.
• Future Care Delivery: As the obesity epidemic grows, telehealth platforms must evolve to address the specific needs of "under-responders" (disproportionately male in this cohort) and provide pathways for managing comorbidities and side effects, moving beyond simple weight monitoring to holistic metabolic management.

Note: As a preprint, these findings have not yet undergone peer review and should be interpreted with caution regarding clinical application.